<?xml version='1.0' encoding='utf-8'?>
<document id="27895114"><sentence text="In Vitro and Clinical Evaluations of the Drug-Drug Interaction Potential of a Metabotropic Glutamate 2/3 Receptor Agonist Prodrug with Intestinal Peptide Transporter 1." /><sentence text="Despite peptide transporter 1 (PEPT1) being responsible for the bioavailability for a variety of drugs, there has been little study of its potential involvement in drug-drug interactions" /><sentence text=" Pomaglumetad methionil, a metabotropic glutamate 2/3 receptor agonist prodrug, utilizes PEPT1 to enhance absorption and bioavailability"><entity charOffset="40-49" id="DDI-PubMed.27895114.s3.e0" text="glutamate" /></sentence><sentence text=" In vitro studies were conducted to guide the decision to conduct a clinical drug interaction study and to inform the clinical study design" /><sentence text=" In vitro investigations determined the prodrug (LY2140023 monohydrate) is a substrate of PEPT1 with Km value of approximately 30 ÂµM, whereas the active moiety (LY404039) is not a PEPT1 substrate" /><sentence text=" In addition, among the eight known PEPT1 substrates evaluated in vitro, valacyclovir was the most potent inhibitor (IC50 = 0"><entity charOffset="73-85" id="DDI-PubMed.27895114.s6.e0" text="valacyclovir" /></sentence><sentence text="46 mM) of PEPT1-mediated uptake of the prodrug" /><sentence text=" Therefore, a clinical drug interaction study was conducted to evaluate the potential interaction between the prodrug and valacyclovir in healthy subjects"><entity charOffset="122-134" id="DDI-PubMed.27895114.s8.e0" text="valacyclovir" /></sentence><sentence text=" No effect of coadministration was observed on the pharmacokinetics of the prodrug, valacyclovir, or either of their active moieties"><entity charOffset="84-96" id="DDI-PubMed.27895114.s9.e0" text="valacyclovir" /></sentence><sentence text=" Although in vitro studies showed potential for the prodrug and valacyclovir interaction via PEPT1, an in vivo study showed no interaction between these two drugs"><entity charOffset="64-76" id="DDI-PubMed.27895114.s10.e0" text="valacyclovir" /></sentence><sentence text=" PEPT1 does not appear to easily saturate because of its high capacity and expression in the intestine" /><sentence text=" Thus, a clinical interaction at PEPT1 is unlikely even with a compound with high affinity for the transporter" /><sentence text="" /></document>